Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25083904 | 0.83 | MAPT (0.56) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL9688868 | 0.81 | LMNA (0.54) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL25883843 | 0.81 | CYP19A1 (0.61) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL10509734 | 0.81 | NPC1 (0.66) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL9852166 | 0.80 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL12890452 | 0.80 | SMN1; SMN2 (0.61) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL2210735 | 0.79 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL16254958 | 0.78 | SMN1; SMN2 (1.00) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9852174 | 0.77 | ADORA3 (0.77) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL12268226 | 0.75 | CYP1A2 (0.48) | NPC1RAB9AMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-0455356-A1 | Substituted 5-amino-1,2,4-thiadiazoles with pharmaceutical activity | LILLY INDUSTRIES LIMITED (GB) | 1991-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | NPC1 503/4885RAB9A 534/4885MEN1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.